NYSEAMERICAN:AST

Asterias Biotherapeutics (AST) Stock Price, News & Analysis

Asterias Biotherapeutics logo
$0.0020 0.00 (0.00%)
As of 07/10/2019

About Asterias Biotherapeutics Stock (NYSEAMERICAN:AST)

Key Stats

Today's Range
$0.0020
$0.0020
50-Day Range
N/A
52-Week Range
$0.51
$2.05
Volume
1,000 shs
Average Volume
136,653 shs
Market Capitalization
$111,318.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Receive AST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asterias Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AST Stock News Headlines

ARTV Artiva Biotherapeutics, Inc.
A deadly mistake in my prediction…
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
CLDI Calidi Biotherapeutics, Inc.
Protalix BioTherapeutics Inc PLX
See More Headlines

AST Stock Analysis - Frequently Asked Questions

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to analysts' expectations of $2.81 million.

Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CorMedix (CRMD), Synergy Pharmaceuticals (SGYP), 22nd Century Group (XXII), Amarin (AMRN), Gilead Sciences (GILD) and Progenics Pharmaceuticals (PGNX).

Company Calendar

Last Earnings
3/28/2017
Today
2/15/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:AST
Previous Symbol
NYSEMKT:AST
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$111,318.00
Optionable
Not Optionable
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NYSEAMERICAN:AST) was last updated on 2/15/2025 by MarketBeat.com Staff
From Our Partners